Bermekimab

Bermekimab^[1] (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A).^[2] As of March 2017^[update]

, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer^[3] and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.^[4]

Bermekimab is being developed by XBiotech Inc.^[5]

References[edit | edit source]

↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Bermekimab, American Medical Association.
↑
↑ "A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 3 March 2017.
↑ "A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 18 December 2018.
↑ "Xilonix™ True Human™ monoclonal antibody by Xbiotech oncology". www.xbiotech.com. XBiotech. Retrieved 3 March 2017.

Bermekimab Resources
Latest articles Most recent articles Ongoing trials	Wikipedia

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Translate this page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Bermekimab, American Medical Association.

[2] ↑

[3] "A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 3 March 2017.

[4] "A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 18 December 2018.

[5] "Xilonix™ True Human™ monoclonal antibody by Xbiotech oncology". www.xbiotech.com. XBiotech. Retrieved 3 March 2017.

[1]

[2]

[3]

[4]

[5]